Patients Often Lose Out in the Tug of War Between Pharma and PBMs
PBMs have imposed accumulators and maximizers to counteract pharma’s copay assistance programs. Drug manufacturers have retaliated by reducing the amount of patient assistance available.
It’s Not Just Convenient. Virtual Care is the Solution to Some of Healthcare’s Most Intractable Problems
Virtual care presents a unique opportunity to achieve the kind of whole-person care that has been discussed in healthcare for decades, if not longer.
Coping With the Ozempic-Wegovy-Mounjaro Tsunami
Insurers are using prior authorization and other managed care strategies to control costs associated with the growing number of prescriptions, on- and off-label, for the weight-loss medications.
Some Lessons Learned Around Alternative Payment Models
Experts say the successes and failures of alternative payment models (APMs) over the past decade have taught us a few things.
Reality Check on Alternative Payment Methods
Alternative payment models are still coming into focus, but so far, they haven’t lived up to the high expectations.
What Does Pear Therapeutics’ Bankruptcy Mean for PDTs?
The company paved the way for prescription digital therapeutics.
The NASH Cupboard, Now Bare, Has Two Candidates
Ocaliva and resmetirom may be approved by the FDA this year.
2 Clarke Drive Cranbury, NJ 08512